A

Anavex Life Sciences Corp

D
AVXL
USD
-0.16
(-2.0513%)
Market Closed
34,856.00
Volume
-0.55
EPS
-
Div Yield
-14.980392
P/E
647,837,749.88
Market Cap
Today
-2.0513%
1 Week
15.234%
1 Month
42.272%
6 Months
98.700%
12 Months
22.830%
Year To Date
-18.114%
All Time
0%

Title:
Anavex Life Sciences Corp

Sector:
Healthcare
Industry:
Biotechnology
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Do you need help or have a question?